Measles Virus Or Mumps Virus Patents (Class 424/212.1)
  • Patent number: 10610469
    Abstract: Calcium phosphate (“CAP”) particles for use in cosmetic, nutraceutic or aesthetic medicine. The particles may be used as carriers for cosmetic, nutraceutic or a factors, as controlled release matrices for the material, and as fillers in cosmetic treatments. The particles may be applied topically or injected or by any other appropriate delivery method.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 7, 2020
    Inventor: Stephen J. D. Bell
  • Patent number: 10391167
    Abstract: The present disclosure relates to a method for inducing humoral immunity in a human or animal, that includes administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane. The mucosal vaccine composition includes at least one antigen derived from a pathogen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Pantoea, Acetobacter, Zymomonas, and Xanthomonas, or a salt of the lipopolysaccharide, wherein the mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: August 27, 2019
    Assignee: NITTO DENKO CORPORATION
    Inventors: Masahiro Fukasaka, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Eiji Kiyotoh, Kyohei Matsushita
  • Patent number: 10111947
    Abstract: The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected in the group of polyvinylpyrrolidone and derivatives thereof, (iii) at least one sugar, (iv) at least two different amino acids, (v) at least two pharmaceutical acceptable salts, wherein at least one of said salts is a phosphate salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: October 30, 2018
    Assignee: Transgene S.A.
    Inventors: Claude Sene, Mélina Chasle
  • Patent number: 10071155
    Abstract: The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: September 11, 2018
    Assignee: NITTO DENKO CORPORATION
    Inventors: Eiji Kiyotoh, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Masahiro Fukasaka, Kyohei Matsushita
  • Patent number: 9248107
    Abstract: Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: wherein R1, R2, and R3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH3)3NO. The formulation is useful for vaccine stabilization.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: February 2, 2016
    Assignee: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: Tianxiao Sun, Philip M. Levesque, Alicja T. Brown, Cynthia K. Lee
  • Publication number: 20150056246
    Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Inventors: David A. Putnam, Joseph Rosenthal, Chung-Jr Huang, Matthew Delisa, Susana Mendez
  • Publication number: 20150037355
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: January 4, 2012
    Publication date: February 5, 2015
    Applicants: SILLAJEN, INC., JENNEREX INC.
    Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • Patent number: 8926961
    Abstract: The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: January 6, 2015
    Assignee: Board Of Trustees of The University Of Arkansas
    Inventor: Mayumi Nakagawa
  • Publication number: 20140294894
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Applicant: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Publication number: 20140227320
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 14, 2014
    Inventors: Shawn P. Iadonato, Kristin Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Publication number: 20140199344
    Abstract: The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: MOR RESEARCH APPLICATIONS LTD.
    Inventors: Shmuel ARIAD, Jacob GOPAS, Daniel BENHARROCH, Irina LAZAREV
  • Publication number: 20140193458
    Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.
    Type: Application
    Filed: March 9, 2012
    Publication date: July 10, 2014
    Inventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
  • Publication number: 20140161826
    Abstract: A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the target is internalized after forming a complex with the composition and the non-self epitope is presented on the cell surface of said diseased cell of an organism after internalization.
    Type: Application
    Filed: April 5, 2012
    Publication date: June 12, 2014
    Inventor: Antonello Pessi
  • Publication number: 20140141041
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Application
    Filed: December 30, 2013
    Publication date: May 22, 2014
    Applicant: VAXIN INC.
    Inventor: De-Chu C. Tang
  • Patent number: 8728491
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: May 20, 2014
    Assignee: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Publication number: 20140127263
    Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 8, 2014
    Applicant: OmniGen Research, L.L.C.
    Inventors: Neil E. Forsberg, Steven B. Puntenney
  • Patent number: 8652482
    Abstract: The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: February 18, 2014
    Assignee: The Board of Trustees of the University of Arkansas
    Inventor: Mayumi Nakagawa
  • Publication number: 20140010840
    Abstract: The present invention provides the complete genomic sequence of the epidemic mumps virus (MuV) strain MuVIowa/us/06. Further, a reverse genetics system was constructed and used to rescue recombinant viral constructs that are attenuated compared to MuVIowa/us/06 and JL vaccine viruses. Such constructs include viral constructs lacking the open reading frame (ORF) of the SH gene (rMuV?SH) and/or incapable of expressing the V protein (rMuV?V).
    Type: Application
    Filed: February 24, 2012
    Publication date: January 9, 2014
    Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventor: Biao He
  • Publication number: 20140004150
    Abstract: The invention provides a vaccine injection, which includes a vaccine and a Traditional Chinese medicinal adjuvant in a mass ratio of 1:0.5-1:10, or a vaccine, a Traditional Chinese medicinal adjuvant and an aluminum adjuvant in a mass ratio of 1:0.5:2.5-1:10:20. The vaccine injection is in the form of powders, and the size of the powders is between 10 and 120 micrometers. The vaccine injection of the present invention is particularly suitable for the needle free injection technology. The invention also provides a preparation method for the vaccine injection.
    Type: Application
    Filed: April 8, 2011
    Publication date: January 2, 2014
    Applicants: CHINA 302 MILITARY HOSPITAL OF PLA
    Inventors: Jiabo Wang, Xiaohe Xiao, Zhewei Wang, Cheng Jin, Qi Li
  • Publication number: 20130344106
    Abstract: The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 26, 2013
    Inventors: ANDRE E. NEL, HYON-JEEN KIM
  • Publication number: 20130323280
    Abstract: The present disclosure provides methods for preparing vesicles. In one aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding the molten mixture of vesicle-forming lipids to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed, wherein in the step of adding the molten mixture of vesicle forming lipids is at a temperature of less than 120° C. In another aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding an aqueous solution comprising an antigen to the molten mixture of vesicle-forming lipids such that antigen-containing vesicles are formed, wherein the resulting mixture is placed under temperature-controlled conditions of less than 60° C. In yet another aspect, the methods involve providing a solution of vesicle forming lipids and adding the solution of vesicle-forming lipids to an aqueous solution comprising an antigen by injection such that antigen-containing vesicles are formed.
    Type: Application
    Filed: January 13, 2012
    Publication date: December 5, 2013
    Applicant: VARIATION BIOTECHNOLOGIES, INC.
    Inventors: David E. Anderson, Yvonne Perrie, Marc Kirchmeier, Jitinder Singh Wilkhu
  • Publication number: 20130309268
    Abstract: A non-mammalian transfer factor, compositions including the non-mammalian transfer factor, and methods for generating and preparing the non-mammalian transfer factor. The non-mammalian transfer factor may have specificity for one or more antigens. A method of using the non-mammalian transfer factor includes administering either antigen-specific non-mammalian transfer factor or antigen non-specific non-mammalian transfer factor to mammals to treat or prevent pathogenic infections in the mammals.
    Type: Application
    Filed: February 22, 2002
    Publication date: November 21, 2013
    Inventors: William J. Hennen, David T. Lisonbee
  • Patent number: 8586364
    Abstract: The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded RNA viruses (NNV or mononegavirales) from cloned deoxyribonucleic acid (cDNA), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated Schwarz measles virus and various recombinant Schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: November 19, 2013
    Assignee: Institut Pasteur
    Inventors: Frédéric Tangy, Pierre Charneau, Yves Jacob
  • Publication number: 20130295114
    Abstract: PVRL4 is a tumor marker that is highly expressed on the surfaces of many carcinomas. Disclosed herein are compositions and methods that provide impetus for using measles virus as an oncolytic agent against PVRL4+ carcinomas and use of PVRL4-binding agents to interfere with viral infection.
    Type: Application
    Filed: January 17, 2012
    Publication date: November 7, 2013
    Inventor: Christopher D. Richardson
  • Publication number: 20130295165
    Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an attenuated or inactivated virus in combination with a non-ionic surfactant vesicle (NISV).
    Type: Application
    Filed: January 13, 2012
    Publication date: November 7, 2013
    Applicant: VARIATION BIOTECHNOLOGIES, INC.
    Inventors: David E. Anderson, Tanvir Ahmed, Jasminka Bozic, Marc Kirchmeier
  • Publication number: 20130202655
    Abstract: Methods and products for treating and/or delaying onset of dysplastic lesions, and wafers for oral administration employ dry powder compositions including myo-inositol. Methods for administering a vaccine for a virus or bacteria to an individual comprising administering a first portion of the vaccine to the individual via one route and administering a second portion via a second, different route. In a specific embodiment, the first route is sublingually. Vaccines are provided in the form of dry powder compositions comprising a combination of nanoparticles and microparticles, or in the form of a wafer which dissolves in water at room temperature in less than about one minute. Storage stable unit dosages of a vaccine are provided by individually packaging individual unit dosages of a dry powder composition comprising the vaccine and a carrier in blister compartments formed of gas and moisture resistant material.
    Type: Application
    Filed: April 22, 2011
    Publication date: August 8, 2013
    Applicant: AKTIV-DRY LLC
    Inventors: Robert E. Sievers, Stephen P. Cape, David McAdams, J'aime Manion, Pankaj Pathak
  • Publication number: 20130045229
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: April 20, 2011
    Publication date: February 21, 2013
    Applicant: KINETA, INC.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Publication number: 20120294830
    Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
    Type: Application
    Filed: July 6, 2012
    Publication date: November 22, 2012
    Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
  • Publication number: 20120258135
    Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.
    Type: Application
    Filed: January 26, 2012
    Publication date: October 11, 2012
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Publication number: 20120171292
    Abstract: The disclosure relates to immunizing agents and devices.
    Type: Application
    Filed: January 3, 2012
    Publication date: July 5, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael J. Sailor, Stephen M. Hedrick, Lou Gu, Laura Ruff, Zhengtao Qin
  • Publication number: 20120093770
    Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 19, 2012
    Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
  • Patent number: 8158416
    Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: April 17, 2012
    Assignee: Crucell Switzerland AG
    Inventors: Martin A. Billeter, Pius Spielhofer, Karin Kalin, Frank Radecke, Henriette Schneider
  • Publication number: 20120045430
    Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.
    Type: Application
    Filed: August 15, 2011
    Publication date: February 23, 2012
    Inventors: Dan Luo, Yougen Li
  • Publication number: 20120039935
    Abstract: The invention provides for a measles vaccine utilizing a human codon-optimized polynucleotide encoding a measles virus polypeptide, such as HA or F protein. Optionally, the vaccine is administered with an adjuvant and is especially useful for immunizing an infant mammal.
    Type: Application
    Filed: June 16, 2010
    Publication date: February 16, 2012
    Applicant: Vical Incorporated
    Inventors: Adrian Vilalta, Gretchen Jimenez, Diane E. Griffin
  • Patent number: 8071334
    Abstract: The invention relates to a method for preparation of soluble N-protein/truncated P-protein complex of a virus of the family Paramyxoviridae, complexes prepared thus and the soluble N-proteins which may be isolated from said complexes. The invention further relates to vaccine compositions comprising said N-protein/truncated P-protein complexes or N-proteins from Paramyxoviridae.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: December 6, 2011
    Assignee: Institut National de la Recherche Agronomique
    Inventors: Jean-Francois Eleouet, Sabine Riffault
  • Publication number: 20110293723
    Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: May 26, 2011
    Publication date: December 1, 2011
    Applicant: Selecta Biosciences, Inc.
    Inventors: Robert L. Bratzler, Grayson B. Lipford, Lloyd Johnston, Charles Zepp
  • Publication number: 20110243988
    Abstract: This invention provides compositions and methods for stabilizing a live attenuated virus in dried formulations. In particular, compositions and methods of preparing a dried vaccine are provided that stabilize the viability of live vaccines such as measles and adenovirus at room temperature.
    Type: Application
    Filed: October 1, 2010
    Publication date: October 6, 2011
    Inventors: Satoshi Ohtake, Vu Truong-Le, Luisa Yee, Russell A. Martin, David Lechuga-Ballesteros
  • Publication number: 20110217244
    Abstract: The use of oxidatively transformed carotenoid or a component thereof to enhance the immune response in a subject for the treatment of infection or to enhance the immune response to an antigen in a subject being immunized. Also disclosed are pharmaceutical compositions and kits containing the oxidatively transformed carotenoid.
    Type: Application
    Filed: October 23, 2008
    Publication date: September 8, 2011
    Applicant: National Research Council of Canada
    Inventors: James Johnston, Bozena Korczak, Graham Burton
  • Patent number: 7993924
    Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: August 9, 2011
    Assignee: Crucell Switzerland AG
    Inventors: Martin A. Billeter, Pius Spielhofer, Karin Kälin, Frank Radecke, Henriette Schneider
  • Publication number: 20110182857
    Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
    Type: Application
    Filed: April 1, 2011
    Publication date: July 28, 2011
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Peter James WATTS, Lisbeth ILLUM
  • Publication number: 20110177120
    Abstract: The present invention relates to the use of live mycobacterium of the M. tuberculosis complex for preparing a medicament, wherein the function of the zmp1-gene is inactivated, pharmaceutical compositions prepared from such mycobacteria as well as a method for the treatment and/or prophylaxis of a disease or medical condition using said pharmaceutical composition.
    Type: Application
    Filed: October 9, 2009
    Publication date: July 21, 2011
    Applicant: UNIVERSITY OF ZURICH
    Inventors: Erik Boettger, Peter Sander
  • Publication number: 20110150927
    Abstract: A micro-particulate dry powder composition comprising a viral particle can be prepared by spray-drying a mixture of the viral particle and a stabilizing carbohydrate using an outlet temperature of no more than 60° C.
    Type: Application
    Filed: July 30, 2010
    Publication date: June 23, 2011
    Applicant: QUADRANT DRUG DELIVERY LIMITED
    Inventor: CHRISTOPHER IAIN GRAINGER
  • Publication number: 20110142881
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Application
    Filed: May 7, 2008
    Publication date: June 16, 2011
    Applicant: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Publication number: 20110135679
    Abstract: The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a pharmaceutically acceptable excipient, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.
    Type: Application
    Filed: December 7, 2008
    Publication date: June 9, 2011
    Applicant: NOVARTIS AG
    Inventors: Padma Malyala, Derek O'Hagan, Manmohan Singh
  • Patent number: 7951587
    Abstract: The invention relates to a recombinant Mononegavirales virus (MV) vector comprising a foreign gene that is flanked by non-coding regions of a MV virus gene.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: May 31, 2011
    Assignee: Intervet International B.V.
    Inventors: Angela Römer-Oberdörfer, Jutta Veits, Teshome Mebatsion
  • Publication number: 20110110979
    Abstract: The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.
    Type: Application
    Filed: April 1, 2009
    Publication date: May 12, 2011
    Applicant: Universite De Lausanne
    Inventor: Denise Nardelli Haefliger
  • Publication number: 20110014231
    Abstract: The present invention provides methods for treating specific populations of cancer patients by immunotherapy. The methods comprise administering an immunogenic composition eliciting an immune response to measles virus to patients having measles virus-immunoreactive cancer cells.
    Type: Application
    Filed: November 5, 2008
    Publication date: January 20, 2011
    Applicant: MOR RESEARCH APPLICATIONS LTD
    Inventors: Shmuel Ariad, Jacob Gopas, Daniel Benharroch, Irina Lazarev
  • Patent number: 7851214
    Abstract: The present invention relates, in general, to a methodology or the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a model for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: December 14, 2010
    Assignee: Crucell Switzerland AG
    Inventors: Martin A. Billeter, Pius Spielhofer, Karin Kälin, Frank Radecke, Henriette Schneider
  • Publication number: 20100285135
    Abstract: Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions.
    Type: Application
    Filed: December 1, 2006
    Publication date: November 11, 2010
    Applicant: NOVARTIS AG
    Inventors: Janet R. Wendorf, Manmohan Singh, Derek T. O'Hagan
  • Publication number: 20100247537
    Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
    Type: Application
    Filed: April 25, 2008
    Publication date: September 30, 2010
    Inventors: Cory Ahonen, Randolph Noelle